Cargando…
Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests
Cancer remains a leading cause of death worldwide, partly owing to late detection which entails limited and often ineffective therapeutic options. Most cancers lack validated screening procedures, and the ones available disclose several drawbacks, leading to low patient compliance and unnecessary wo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047029/ https://www.ncbi.nlm.nih.gov/pubmed/36980276 http://dx.doi.org/10.3390/cells12060935 |
_version_ | 1785013819631730688 |
---|---|
author | Brito-Rocha, Tiago Constâncio, Vera Henrique, Rui Jerónimo, Carmen |
author_facet | Brito-Rocha, Tiago Constâncio, Vera Henrique, Rui Jerónimo, Carmen |
author_sort | Brito-Rocha, Tiago |
collection | PubMed |
description | Cancer remains a leading cause of death worldwide, partly owing to late detection which entails limited and often ineffective therapeutic options. Most cancers lack validated screening procedures, and the ones available disclose several drawbacks, leading to low patient compliance and unnecessary workups, adding up the costs to healthcare systems. Hence, there is a great need for innovative, accurate, and minimally invasive tools for early cancer detection. In recent years, multi-cancer early detection (MCED) tests emerged as a promising screening tool, combining molecular analysis of tumor-related markers present in body fluids with artificial intelligence to simultaneously detect a variety of cancers and further discriminate the underlying cancer type. Herein, we aim to provide a highlight of the variety of strategies currently under development concerning MCED, as well as the major factors which are preventing clinical implementation. Although MCED tests depict great potential for clinical application, large-scale clinical validation studies are still lacking. |
format | Online Article Text |
id | pubmed-10047029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100470292023-03-29 Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests Brito-Rocha, Tiago Constâncio, Vera Henrique, Rui Jerónimo, Carmen Cells Review Cancer remains a leading cause of death worldwide, partly owing to late detection which entails limited and often ineffective therapeutic options. Most cancers lack validated screening procedures, and the ones available disclose several drawbacks, leading to low patient compliance and unnecessary workups, adding up the costs to healthcare systems. Hence, there is a great need for innovative, accurate, and minimally invasive tools for early cancer detection. In recent years, multi-cancer early detection (MCED) tests emerged as a promising screening tool, combining molecular analysis of tumor-related markers present in body fluids with artificial intelligence to simultaneously detect a variety of cancers and further discriminate the underlying cancer type. Herein, we aim to provide a highlight of the variety of strategies currently under development concerning MCED, as well as the major factors which are preventing clinical implementation. Although MCED tests depict great potential for clinical application, large-scale clinical validation studies are still lacking. MDPI 2023-03-18 /pmc/articles/PMC10047029/ /pubmed/36980276 http://dx.doi.org/10.3390/cells12060935 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Brito-Rocha, Tiago Constâncio, Vera Henrique, Rui Jerónimo, Carmen Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests |
title | Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests |
title_full | Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests |
title_fullStr | Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests |
title_full_unstemmed | Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests |
title_short | Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests |
title_sort | shifting the cancer screening paradigm: the rising potential of blood-based multi-cancer early detection tests |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047029/ https://www.ncbi.nlm.nih.gov/pubmed/36980276 http://dx.doi.org/10.3390/cells12060935 |
work_keys_str_mv | AT britorochatiago shiftingthecancerscreeningparadigmtherisingpotentialofbloodbasedmulticancerearlydetectiontests AT constanciovera shiftingthecancerscreeningparadigmtherisingpotentialofbloodbasedmulticancerearlydetectiontests AT henriquerui shiftingthecancerscreeningparadigmtherisingpotentialofbloodbasedmulticancerearlydetectiontests AT jeronimocarmen shiftingthecancerscreeningparadigmtherisingpotentialofbloodbasedmulticancerearlydetectiontests |